{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:37:38Z","timestamp":1682505458481},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,10,27]],"date-time":"2013-10-27T00:00:00Z","timestamp":1382832000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00044-013-0852-5","type":"journal-article","created":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T06:33:58Z","timestamp":1382769238000},"page":"2622-2632","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of surface area features of structurally diverse molecules for Bcr\/Abl kinase inhibitory activity and antiproliferative activity"],"prefix":"10.1007","volume":"23","author":[{"given":"N. S. Hari Narayana","family":"Moorthy","sequence":"first","affiliation":[]},{"given":"C.","family":"Karthikeyan","sequence":"additional","affiliation":[]},{"given":"E.","family":"Manivannan","sequence":"additional","affiliation":[]},{"given":"P.","family":"Trivedi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,10,27]]},"reference":[{"key":"852_CR1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmcl.2005.11.042","volume":"16","author":"T Asaki","year":"2006","unstructured":"Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T (2006) Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 16:1421\u20131425","journal-title":"Bioorg Med Chem Lett"},{"key":"852_CR2","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL (2006) Dasatinib, (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539","journal-title":"Blood"},{"key":"852_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-1280(99)00360-7","volume":"503","author":"C Cruciani","year":"2000","unstructured":"Cruciani C, Crivori P, Carrupt PA, Testa B (2000) Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struct (Theochem) 503:17\u201330","journal-title":"J Mol Struct (Theochem)"},{"key":"852_CR4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A DeKlein","year":"1982","unstructured":"DeKlein A, Van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bostooma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765\u2013767","journal-title":"Nature"},{"key":"852_CR5","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1016\/j.bmcl.2010.05.043","volume":"20","author":"X Deng","year":"2010","unstructured":"Deng X, Lim SM, Zhang J, Gray NS (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. Bioorg Med Chem Lett 20:4196\u20134200","journal-title":"Bioorg Med Chem Lett"},{"key":"852_CR6","first-page":"409","volume":"37","author":"J Durbin","year":"1950","unstructured":"Durbin J, Watson GS (1950) Testing for serial correlation in least squares regression\u00a01. Biometrika 37:409\u2013428","journal-title":"Biometrika"},{"key":"852_CR7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1468-0734.2002.00066.x","volume":"6","author":"S Faderl","year":"2002","unstructured":"Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM (2002) Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014current concepts and future perspectives. Rev Clin Exp Haematol 6:142\u2013160","journal-title":"Rev Clin Exp Haematol"},{"key":"852_CR8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1021\/ci000306p","volume":"41","author":"H Gao","year":"2001","unstructured":"Gao H (2001) Application of BCUT metrics and genetic algorithm in binary QSAR analysis. J Chem Inf Comput Sci 41:402\u2013407","journal-title":"J Chem Inf Comput Sci"},{"key":"852_CR9","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1016\/j.bmcl.2005.05.122","volume":"15","author":"MP Gonzalez","year":"2005","unstructured":"Gonzalez MP, Teran C, Teijeira M, Besada P, Gonzalez-Moa MJ (2005) BCUT descriptors for predicting affinity toward A(3) adenosine receptors. Bioorg Med Chem Lett 15:3491\u20133495","journal-title":"Bioorg Med Chem Lett"},{"key":"852_CR10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","volume":"10","author":"EA Harrington","year":"2004","unstructured":"Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262\u2013267","journal-title":"Nat Med"},{"key":"852_CR11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jmgm.2007.03.001","volume":"26","author":"AAS Juan","year":"2007","unstructured":"Juan AAS (2007) Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein. J Mol Graph Modell 26:482\u2013493","journal-title":"J Mol Graph Modell"},{"key":"852_CR12","first-page":"7149","volume":"62","author":"P Rosee La","year":"2002","unstructured":"La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker B (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that causes resistance to imatinib mesylate (Gleevec STI571). Cancer Res 62:7149\u20137153","journal-title":"Cancer Res"},{"key":"852_CR13","unstructured":"Lin A (2002) QuaSAR-descriptors. J Chem Comput Group. http:\/\/www.chemcomp.com\/Journal_of_CCG\/Features\/descr.htm"},{"key":"852_CR14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinbiochem.2004.05.006","volume":"37","author":"S Madhusudan","year":"2004","unstructured":"Madhusudan S, Ganesan TS (2004) Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 37:618\u2013635","journal-title":"Clin Biochem"},{"key":"852_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","volume":"1754","author":"PW Manley","year":"2005","unstructured":"Manley PW, Cowan-Jacob SW, Mestan J (2005) Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophy Acta 1754:3\u201313","journal-title":"Biochim Biophy Acta"},{"key":"852_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.chemolab.2011.02.010","volume":"109","author":"NSHN Moorthy","year":"2011","unstructured":"Moorthy NSHN, Ramos MJ, Fernandes PA (2011a) Structural analysis of \u03b1-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. J Chemom Intell Lab Sys 109:101\u2013112","journal-title":"J Chemom Intell Lab Sys"},{"key":"852_CR17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1039\/c1ra00131k","volume":"1","author":"NSHN Moorthy","year":"2011","unstructured":"Moorthy NSHN, Ramos MJ, Fernandes PA (2011b) hERG binding feature analysis of structurally diverse compounds by QSAR and fragmental analysis. RSC Adv 1:1126\u20131136","journal-title":"RSC Adv"},{"key":"852_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/157018011793663859","volume":"8","author":"NSHN Moorthy","year":"2011","unstructured":"Moorthy NSHN, Ramos MJ, Fernandes PA (2011c) QSAR analysis of isosteviol derivatives as \u03b1-glucosidase inhibitors with element count and other descriptors. Lett Drug Des Discov 8:14\u201325","journal-title":"Lett Drug Des Discov"},{"key":"852_CR19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/1062936X.2012.666264","volume":"23","author":"NSHN Moorthy","year":"2012","unstructured":"Moorthy NSHN, Ramos MJ, Fernandes PA (2012) Analysis of van der Waals surface area properties for human ether-a-go\u2013go-related gene blocking activity: computational study on structurally diverse compounds. SAR QSAR Environ Res 23:521\u2013536","journal-title":"SAR QSAR Environ Res"},{"key":"852_CR20","doi-asserted-by":"crossref","unstructured":"Moorthy NSHN, Cerquira NMFSA, Ramos MJ, Fernandes PA (2013) Combined ligand and structure based binding mode analysis of oxidosqualene cyclase inhibitors. RSC Adv doi: 10.1039\/c3ra43670e","DOI":"10.1039\/c3ra43670e"},{"key":"852_CR21","first-page":"1497","volume":"132","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497","journal-title":"Science"},{"key":"852_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundarmoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"852_CR23","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1021\/jm0705713","volume":"50","author":"L Peltason","year":"2007","unstructured":"Peltason L, Bajorath J (2007) SAR index: quantifying the nature of structure-activity relationships. J Med Chem 50:5571\u20135578","journal-title":"J Med Chem"},{"key":"852_CR24","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/MCB.13.3.1728","volume":"13","author":"AM Pendergast","year":"1993","unstructured":"Pendergast AM, Gishizky ML, Havlik MH, Witte ON (1993) SH1 domain autophosphorylation of P210 BCR\/ABL is required for transformation but not growth factor independence. Mol Cell Biol 13:1728\u20131736","journal-title":"Mol Cell Biol"},{"key":"852_CR25","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1016\/j.bmcl.2007.05.067","volume":"17","author":"Z Rachid","year":"2007","unstructured":"Rachid Z, Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ (2007) Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl\/DNA targeting properties. Bioorg Med Chem Lett 17:4248\u20134253","journal-title":"Bioorg Med Chem Lett"},{"key":"852_CR26","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.bmc.2010.01.051","volume":"18","author":"MV Ramana Reddy","year":"2010","unstructured":"Ramana Reddy MV, Pallela VR, Cosenza SC, Mallireddigari MR, Patti R, Bonagura M, Truongcao M, Akula B, Jatiani SS, Reddy EP (2010) Design, synthesis and evaluation of (E)-a-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorg Med Chem 18:2317\u20132326","journal-title":"Bioorg Med Chem"},{"key":"852_CR27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"852_CR28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"852_CR29","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1016\/j.bmc.2005.04.065","volume":"13","author":"R Thaimattam","year":"2005","unstructured":"Thaimattam R, Daga RR, Banerjee R, Iqbal J (2005) 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem 13:4704\u20134712","journal-title":"Bioorg Med Chem"},{"key":"852_CR30","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.bmcl.2011.04.060","volume":"21","author":"M Thomas","year":"2011","unstructured":"Thomas M, Huang WS, Wen D, Zhu X, Wang Y, Metcalf CA, Liu S, Chen I, Romero J, Zou D, Sundaramoorthi R, Li F, Qi J, Cai L, Zhou T, Commodore L, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Iuliucci J, Rivera VM, Sawyer TK, Dalgarno DC, Clackson T, Shakespeare WC (2011) Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR\u2013ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett 21:3743\u20133748","journal-title":"Bioorg Med Chem Lett"},{"key":"852_CR31","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Change CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790\u20135797","journal-title":"Cancer Res"},{"key":"852_CR32","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.bmcl.2011.02.029","volume":"21","author":"D Wang","year":"2011","unstructured":"Wang D, Zhang Z, Lu X, Feng Y, Luo K, Gan J, Yingxue L, Wana J, Li X, Zhang F, Tu Z, Cai Q, Ren X, Ding K (2011) Hybrid compounds as new Bcr\/Abl inhibitors. Bioorg Med Chem Lett 21:1965\u20131968","journal-title":"Bioorg Med Chem Lett"},{"key":"852_CR33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood-2002-01-0288","volume":"101","author":"M Warmuth","year":"2003","unstructured":"Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M (2003) Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate\u2013resistant Bcr-Abl kinases. Blood 101:664\u2013972","journal-title":"Blood"},{"key":"852_CR34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/jm8014102","volume":"52","author":"M Wawer","year":"2009","unstructured":"Wawer M, Peltason L, Bajorath J (2009) Elucidation of structure-activity relationship pathways in biological screening data. J Med Chem 52:1075\u20131080","journal-title":"J Med Chem"},{"key":"852_CR35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"852_CR36","first-page":"4244","volume":"62","author":"D Wisniewski","year":"2002","unstructured":"Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornman WG, Bertino JR, Kuriyan J, Clarkson B (2002) Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinase. Cancer Res 62:4244\u20134255","journal-title":"Cancer Res"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-013-0852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00044-013-0852-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-013-0852-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T11:34:54Z","timestamp":1558524894000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00044-013-0852-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,27]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s00044-013-0852-5","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,27]]}}}